FREMONT, Calif. & YANTAI, China--(BUSINESS WIRE)--MabPlex International Ltd. (MabPlex), a global CRO/CMO service provider specializing in the development and manufacturing of antibody therapeutics and antibody-drug conjugates (ADC), today announced that it has broken ground on the expansion of its biomanufacturing facilities in China. The current 275,000 sq. ft. facility will soon be running at full capacity. In order to effectively serve customers better MabPlex is expanding their current CDMO facility. The new 428,000 sq. ft. facility is expected to be completed by August of 2017. The Utility and HVAC validation should be finished by December 2017 and the fill/finish facility will be completely validated by March of 2018. “With this expansion we believe that we will be able to meet our customers’ needs in biologics for the foreseeable future,” says Qibin Liang, President of MabPlex.
The current 275,000 sq. ft. facility will be entirely converted to ADC manufacturing and development space while the new 428,000 sq. ft. facility will be for mAb and other biologic manufacturing. This expansion will allow for six complete 2,000L bioreactor suites or 6 independent manufacturing lines (6x25L, 6x200L, 6x500L and 12x2,000L single use bioreactors). Six purification suites, a 37,000sq ft. cGMP Warehouse, and fill finish lines with capabilities up to 10,000 vials/hr. for mAb and 12,000 vials/hr. for ADC will be housed in these new buildings.
About MabPlex
MabPlex, founded in 2013, specializes in providing one-stop biologics development and manufacturing solutions to customers globally with our services from cell line development and process development to GMP manufacturing. Our technical expertise allows us to provide effective and high-quality solutions for monoclonal antibody and ADC therapeutics to the biopharmaceutical industry. With this, MabPlex delivers our commitment to our partners through our quality manufacturing, meeting their expectations.